EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study

Nima Kokabi iD, Linzi Arndt-Webster, Bernard Chen, David Brandon, Ila Sethi, Amir Davarpanahfakhr, James Galt, Mohammad Elsayed, Zachary Bercu, Mircea Cristescu, S Cheenu Kappadath, David M Schuster

European Journal of Nuclear Medicine and Molecular Imaging · 2023

DOI: 10.1007/s00259-023-06111-9 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Nima Kokabi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Interventional Radiology and Image-Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, At…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Embolization, Therapeutic, Liver Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Radiological Society of North America, Sirtex Medical Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is an increasing body of evidence indicating Y90 dose thresholds for tumor response and treatment-related toxicity. These thresholds are poorly studied in resin Y90, particularly in hepatocellular carcinoma (HCC).

Purpose

To evaluate the efficacy of prospective voxel-based dosimetry for predicting treatment response and adverse events (AEs) in patients with HCC undergoing resin-based Y90 radioembolization. Materials and methods This correlative study was based on a prospective single-arm clinical trial (NCT04172714), which evaluated the efficacy of low/scout (555 MBq) activity of resin-based Y90 for treatment planning. Partition model was used with goal of tumor dose (TD) > 200 Gy and non-tumoral liver dose (NTLD) < 70 Gy for non-segmental therapies. Single compartment dose of 200 Gy was used for segmentectomies. Prescribed Y90 activity minus scout activity was administered for therapeutic Y90 followed by Y90-PET/CT. Sureplan® (MIM Software, Cleveland, OH) was used for dosimetry analysis. Treatment response was evaluated at 3 and 6 months. Receiver operating characteristic curve determined TD response threshold for objective response (OR) and complete response (CR) as well as non-tumor liver dose (NTLD) threshold that predicted AEs.

Results

N = 30 patients were treated with 33 tumors (19 segmental and 14 non-segmental). One patient died before the first imaging, and clinical follow-up was excluded from this analysis. Overall, 26 (81%) of the tumors had an OR and 23 (72%) had a CR. A mean TD of 253 Gy predicted an OR with 92% sensitivity and 83% specificity (area under the curve (AUC = 0.929, p < 0.001). A mean TD of 337 Gy predicted a CR with 83% sensitivity and 89% specificity (AUC = 0.845, p < 0.001). A mean NTLD of 81 and 87 Gy predicted grade 3 AEs with 100% sensitivity and 100% specificity in the non-segmental cohort at 3- and 6-month post Y90, respectively.

Conclusion

In patients with HCC undergoing resin-based Y90, there are dose response and dose toxicity thresholds directly affecting outcomes. Clinical trial number: NCT04172714.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsHumansMicrospheresPositron Emission Tomography Computed TomographyProspective StudiesTreatment OutcomeYttrium Radioisotopes

Stichwörter der Autor:innen

HCCLiver dose toxicity thresholdResin microspheresTumor dose response thresholdYttrium-90

Substanzen

Yttrium Radioisotopes

Autor:innen und Institutionen

  • Division of Interventional Radiology and Image-Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA. nkokabi@emory.edu.
  • Division of Interventional Radiology, Department of Radiology, Mount Sinai School of Medicine, New York, NY, USA.
  • Division of Interventional Radiology, Department of Radiology, University of Texas at San Antonio, San Antonio, TX, USA.
  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA.
  • Division of Abdominal Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA.
  • Division of Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Nima Kokabi

Förderung

  • NCI NIH HHS
  • Radiological Society of North America
  • Sirtex Medical Ltd

Zitieren

APA

Kokabi, N., Arndt-Webster, L., Chen, B., Brandon, D., Sethi, I., Davarpanahfakhr, A., Galt, J., Elsayed, M., Bercu, Z., Cristescu, M., Kappadath, S. C., & Schuster, D. M. (2023). Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06111-9

Vancouver

Kokabi N, Arndt-Webster L, Chen B, Brandon D, Sethi I, Davarpanahfakhr A, et al. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06111-9

BibTeX
@article{Kokabi2023,
  author = {Kokabi, Nima and Arndt-Webster, Linzi and Chen, Bernard and Brandon, David and Sethi, Ila and Davarpanahfakhr, Amir and Galt, James and Elsayed, Mohammad and Bercu, Zachary and Cristescu, Mircea and Kappadath, S Cheenu and Schuster, David M},
  title = {Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  doi = {10.1007/s00259-023-06111-9}
}
Kostenlos starten →